Reviva Pharma Closes $10 Mln Public Offering, Boosts Cash Runway to Q1 2027

Reviva Pharmaceuticals Holdings has closed a $10 mln public offering, raising its cash and cash equivalents to $23 mln. The company now expects its cash runway to last through Q1 2027. The funds will be used for research and development activities, including the RECOVER-2 Phase 3 trial for Brilaroxazine in Schizophrenia, and for working capital and other general corporate purposes.